2026 is shaping up to be a pivotal year for healthcare policy, with changes unfolding at both the federal and state levels. This panel will break down the most consequential policy shifts ahead, including the future of ACA subsidies, drug pricing and PBM reform, evolving state legislative priorities, FDA regulatory shifts impacting drugs, devices, and digital health, and the emergence of new value-based care models such as CMS’s ACCESS model for chronic condition management. Panelists will examine what these developments mean for payers and providers, where regulatory and market uncertainty remains, and how organizations can prepare strategically for the next phase of healthcare policy and delivery.